Trial Profile

A Phase 1/2 Study of V940 Plus Pembrolizumab With or Without Enfortumab Vedotin in Muscle-Invasive Urothelial Carcinoma (MIUC) (INTerpath-005)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 07 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Intismeran autogene (Primary) ; Pembrolizumab (Primary)
Indications Urogenital cancer
Focus Therapeutic Use
Acronyms INTerpath-005; V940-005
Sponsors Merck Sharp & Dohme

Most Recent Events

29 Jan 2025 Planned End Date changed from 8 Apr 2031 to 20 Oct 2031.
29 Jan 2025 Planned primary completion date changed from 8 Oct 2026 to 23 Apr 2027.
16 Oct 2024 Planned number of patients changed from 200 to 230.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com